Adjuvant Therapy for Intermediate Risk HER2 Positive, Lymph Node Negative Early Breast Cancer With Chemotherapy Combined Target Therapy

NCT06711068 · clinicaltrials.gov ↗

RECRUITING

Status

8077

Enrollment

OTHER

Sponsor class

Conditions

HER2-positive Breast Cancer

Sponsor

Shu Wang